Table 4.
Patients without atrial fibrillation: age-sex standardised incidence rates per 1000 person years (py) of outcomes by database
| Drug | QResearch | CPRD | |||||
|---|---|---|---|---|---|---|---|
| Person years | No of events | Age-sex standardised rate per 1000 py (95% CI) | Person years | No of events | Age-sex standardised rate per 1000 py (95% CI) | ||
| Major bleeding | |||||||
| Warfarin | 39 335 | 1132 | 29.2 (27.5 to 30.9) | 10 796 | 378 | 35.2 (31.6 to 38.7) | |
| Dabigatran | 1129 | 33 | 31.0 (18.8 to 43.1) | 183 | 6 | 28.6 (4.2 to 53.0) | |
| Rivaroxaban | 8066 | 238 | 29.4 (25.6 to 33.1) | 1143 | 41 | 34.9 (24.0 to 45.7) | |
| Apixaban | 3273 | 71 | 18.3 (13.6 to 23.1) | 219 | <5 | 5.9 (0.0 to 13.0) | |
| Intracranial bleed | |||||||
| Warfarin | 39 929 | 244 | 6.3 (5.5 to 7.1) | 10 952 | 78 | 7.2 (5.6 to 8.8) | |
| Dabigatran | 1137 | <5 | 2.9 (0.0 to 5.8) | 184 | <5 | 3.5 (0.0 to 10.3) | |
| Rivaroxaban | 8155 | 29 | 3.5 (2.2 to 4.8) | 1156 | <5 | 2.7 (0.0 to 5.4) | |
| Apixaban | 3297 | 19 | 5.2 (2.7 to 7.7) | 220 | 0 | NA | |
| Haematuria | |||||||
| Warfarin | 39 685 | 351 | 8.9 (8.0 to 9.8) | 10 897 | 109 | 10.0 (8.1 to 11.9) | |
| Dabigatran | 1133 | 8 | 7.9 (2.0 to 13.8) | 184 | <5 | 8.4 (0.0 to 25.0) | |
| Rivaroxaban | 8119 | 71 | 9.0 (6.9 to 11.1) | 1150 | 11 | 9.2 (3.7 to 14.7) | |
| Apixaban | 3291 | 21 | 4.3 (2.4 to 6.1) | 219 | <5 | 3.0 (0.0 to 7.2) | |
| Haemoptysis | |||||||
| Warfarin | 39 912 | 65 | 1.6 (1.2 to 2.0) | 10 950 | 24 | 2.2 (1.3 to 3.0) | |
| Dabigatran | 1137 | <5 | 2.3 (0.0 to 5.5) | 184 | 0 | NA | |
| Rivaroxaban | 8151 | 16 | 1.9 (1.0 to 2.9) | 1155 | <5 | 3.8 (0.1 to 7.6) | |
| Apixaban | 3300 | <5 | 0.3 (0.0 to 0.8) | 220 | 0 | NA | |
| All gastrointestinal bleed | |||||||
| Warfarin | 39 684 | 485 | 12.4 (11.3 to 13.5) | 10 885 | 171 | 15.9 (13.5 to 18.2) | |
| Dabigatran | 1133 | 19 | 17.7 (8.1 to 27.4) | 184 | <5 | 16.6 (0.1 to 33.1) | |
| Rivaroxaban | 8114 | 126 | 15.2 (12.5 to 17.9) | 1150 | 22 | 18.8 (10.8 to 26.9) | |
| Apixaban | 3286 | 31 | 8.8 (5.2 to 12.3) | 220 | <5 | 2.9 (0.0 to 8.6) | |
| Upper gastrointestinal bleed | |||||||
| Warfarin | 39 719 | 431 | 11.1 (10.0 to 12.1) | 10 896 | 152 | 14.1 (11.9 to 16.4) | |
| Dabigatran | 1134 | 16 | 15.6 (6.3 to 24.9) | 184 | <5 | 16.6 (0.1 to 33.1) | |
| Rivaroxaban | 8116 | 117 | 14.0 (11.5 to 16.6) | 1150 | 22 | 18.8 (10.8 to 26.8) | |
| Apixaban | 3288 | 29 | 8.0 (4.6 to 11.4) | 220 | <5 | 2.9 (0.0 to 8.6) | |
| Rectal bleed | |||||||
| Warfarin | 39 917 | 62 | 1.6 (1.2 to 2.0) | 10 949 | 21 | 1.9 (1.1 to 2.7) | |
| Dabigatran | 1136 | <5 | 2.1 (0.0 to 4.6) | 184 | 0 | NA | |
| Rivaroxaban | 8155 | 9 | 1.1 (0.4 to 1.9) | 1156 | 0 | NA | |
| Apixaban | 3298 | <5 | 0.7 (0.0 to 1.8) | 220 | 0 | NA | |
| Ischaemic stroke | |||||||
| Warfarin | 34 121 | 371 | 11.2 (10.1 to 12.4) | 9459 | 109 | 11.6 (9.4 to 13.8) | |
| Dabigatran | 755 | 19 | 20.8 (10.7 to 30.9) | 117 | <5 | 21.1 (0.0 to 45.1) | |
| Rivaroxaban | 6996 | 83 | 11.8 (9.2 to 14.3) | 990 | 9 | 7.9 (2.6 to 13.3) | |
| Apixaban | 2311 | 44 | 15.4 (10.6 to 20.3) | 121 | <5 | 17.5 (0.0 to 37.3) | |
| Venous thromboembolism | |||||||
| Warfarin | 18 496 | 766 | 41.0 (38.1 to 44.0) | 4526 | 182 | 40.0 (34.2 to 45.9) | |
| Dabigatran | 1055 | 10 | 9.7 (3.5 to 15.9) | 166 | 6 | 35.1 (5.0 to 65.1) | |
| Rivaroxaban | 4001 | 688 | 180.3 (166.5 to 194.1) | 532 | 112 | 239.7 (193.7 to 285.8) | |
| Apixaban | 2748 | 89 | 44.0 (33.4 to 54.7) | 188 | <5 | 11.7 (0.0 to 25.0) | |
| Mortality | |||||||
| Warfarin | 39 960 | 2226 | 58.4 (56.0 to 60.8) | 10 963 | 606 | 56.6 (52.1 to 61.1) | |
| Dabigatran | 1137 | 75 | 67.4 (41.7 to 93.0) | 184 | 14 | 60.1 (26.9 to 93.2) | |
| Rivaroxaban | 8158 | 758 | 87.1 (80.8 to 93.3) | 1156 | 130 | 108.4 (89.3 to 127.6) | |
| Apixaban | 3301 | 312 | 72.8 (63.9 to 81.7) | 220 | 21 | 86.2 (25.4 to 146.9) | |
NA=not applicable.